TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02575053

Intervention type: PROCEDURE
Intervention: assessment of a new latex protocol
Description: 1. All powdered latex surgical gloves are removed from the operating theatres, recovery room and surroundings starting from 01-07-2015 in order to create a latex safe environment.~   Steps 2 and 3 remain unchanged in respect to ASA( American Society of Anesthesiologists) protocol.~2. Removal of all materials containing latex from the resuscitation carts.~3. Further requirements in case of latex allergic patients:~   * Identification of patients with (suspected) latex allergy.~  * All materials used during the procedure (catheters, drains, monitoring equipment,...) should be checked for latex.~All latex containing materials should be removed from the room and latex free alternatives should be available.~* All staff present in the room should use latex free synthetic gloves.~* Operating tables and supports should be made of latex free material or should be covered with blankets.~* The entire OR staff is thoroughly educated concerning the latex safe protocol.
Study: NCT00966420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traction assisted endoscopic mucosa resection
Description: A haemoclip is connected to suture material and will be fixed (next) to a polyp to allow traction and lifting the lesion in order to facilitate its resection with a loop.
Study: NCT02330822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: This material is going to be injected into the extraction socket in order to promote bone healing.
Study: NCT04171518

Intervention type: DEVICE
Intervention: Catalys Precision Laser System
Description: Cataract surgeons to create a precise anterior capsulotomy and/or subsequent fragmentation (phacofragmentation) of the crystalline lens using the Catalys Precision Laser System
Study: NCT02219321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine infusion
Description: Lidocaine intravenous 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg /kg /hour for 4 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion
Description: A continuous intravenous infusion of saline at the same volume with lidocaine infusion for 4 hours
Study: NCT02081404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: standard dose of proton pump inhibitor by mouth once a day for 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03001960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preloading before TAVI
Description: Preloading with Aspirin and Clopidogrel before TAVI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postloading after TAVI
Description: Postloading with Aspirin and Clopidogrel after TAVI
Study: NCT01898936

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pretreatment with CO2 laser before photodynamic therapy
Description: The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluator.~The PDT procedure includes application of Metvix cream on the skin on both symmetrical areas with a thickness of approximately 1 mm, plastic covering for 30 minutes before entering daylight for 2 hours.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Only photodynamic therapy
Study: NCT02254577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endometrin® plus Progesterone in Oil (PIO)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone in Oil (PIO) Only
Study: NCT00310804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)
Description: One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)
Description: One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)
Description: One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)
Description: One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).
Study: NCT03778853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib Hydrochloride ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.~Other Name: AL3818
Study: NCT00445224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip Progressive Resistive Exercise
Description: Hip Progressive Resistance Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening hip abduction ad external rotation musculature.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quad Progressive Resistive Exercises
Description: Quad Progressive Resistive Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening quadriceps musculature with straight leg raises and quadriceps isometrics.
Study: NCT03327012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Panlongqi Tablet
Description: Panlongqi Tablet:1.2g,3times a day, oral, for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment of Panlongqi placebo
Description: Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.
Study: NCT02366559

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyfrecator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 532 nm Q-switched Nd:YAG laser
Study: NCT03062592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pine nut oil
Description: Subjects are supplemented with either no oil, hydrolyzed oil or non-hydrolyzed oil in combination with an OGTT

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pine nut oil
Description: Subjects are supplemented with either no oil, hydrolyzed oil or non-hydrolyzed oil in combination with an OGTT
Study: NCT00745693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endothelin-1
Description: Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endothelin-1
Description: Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123 and BQ-788
Description: 1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123 and BQ-788
Description: 1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography
Study: NCT02874365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biopsies
Description: intestinal biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biopsies
Description: intestinal biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biopsies
Description: intestinal biopsies

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endoscopic biopsies
Description: intestinal biopsies
Study: NCT01671423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: See Prednisone arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See Placebo arm description
Study: NCT00981513

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent live attenuated seasonal influenza vaccine
Description: One dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent live attenuated pandemic influenza vaccine
Description: One dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: One dose
Study: NCT00943579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan®
Description: Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.
Study: NCT04201990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab and Apatinib
Description: Camrelizumab, iv, Q3W; Apatinib, po, QD
Study: NCT01855451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: RT (70 Gy in 35 fractions)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: RT (70 Gy in 35 fractions)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study: NCT02401321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Complete Taking Care of Her program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caregiver-Assisted Training
Description: Complete Taking Care of Her program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03294525

Intervention type: DRUG
Intervention: Escitalopram Pill
Description: escitalopram 10\~20mg/day

Intervention type: DRUG
Intervention: Duloxetine
Description: duloxetine 30\~120mg/day

Intervention type: DRUG
Intervention: Mirtazapine Pill
Description: Mirtazapine 15\~45mg/day

Intervention type: DRUG
Intervention: Other Antidepressants
Study: NCT01671813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Brentuximab vedotin will be given intravenously as outlined in treatment arm.
Study: NCT03926845

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isobutylamido-thiazolyl-resorcinol Cream 0.2%
Description: Each bottle contains Isobutylamido-thiazolyl-resorcinol cream 0.2% to be applied on the entire face twice daily for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Each bottle contains vehicle cream to be applied on the entire face twice daily for 12 weeks.
Study: NCT02269787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Telephone Monitoring
Description: Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
Study: NCT01038804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM155
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: intravenous infusion
Study: NCT04636424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assesment of gait
Description: speed and weight distribution during gait

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assesment of gait
Description: speed and weight distribution during gait
Study: NCT02558673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TMAO dietary precursors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TMAO dietary precursors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TMAO dietary precursors

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (or active comparator)
Study: NCT04532385

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea extract
Description: 400 mg capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg capsule
Study: NCT03800888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily SMS reminders for TB patients
Description: Daily SMS Medication reminders will be sent to TB patients to remind them take their medications.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Notifications for social supporters
Description: SMS Notifications will be sent to social supporters to assit TB patients take their medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Notifications for social supporters
Description: SMS Notifications will be sent to social supporters to assit TB patients take their medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly SMS remiders
Description: Weekly SMS reminders sent to TB patients to remind them take medication
Study: NCT03585218

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inhalation of essential oils
Description: Intervention Inhalation of essential oils: From the T1 (2nd Cycle CT), Experimental Group Arms will undergo the inhalation of the hedonic aroma selected by them at the time of chemotherapy (among several types of aromas). It is intended that the participant, when receiving the CT, inhales the aroma phase-in and under the investigator's observation until the end of the treatment (about two hours). The inhalation of essential oils will occur using cotton rolls impregnated with the selected oil. The control group is not subject to intervention during chemotherapy treatment.
Study: NCT00940979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of Integuseal sealant
Description: Microbial sealant (integuseal) applied with a sponge applicator
Study: NCT00777777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eSVS, saphenous vein supporting mesh
Description: Surgical coronary artery bypass grafting to the right coronary artery and the circumflex coronary artery with saphenous vein grafts, one will be supported by the eSVS(TM).
Study: NCT03926689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS messages
Description: A package of at least monthly SMS messages delivered to all adults in households with an individual in the 1000-day period between pregnancy and a child turning 2 years of age.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard SII SBCC
Description: Home visits/IPC; community events including food demo and key life events; and Bhanchhin Aama radio program episodes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard SII SBCC
Description: Home visits/IPC; community events including food demo and key life events; and Bhanchhin Aama radio program episodes
Study: NCT03101774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle training
Description: Threshold inspiratory muscle training device (Threshold Inspiration Muscle Trainer, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resistive inspiratory muscle training
Description: Resistive inspiratory muscle training device(PFLEX, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Conventional therapy without any inspiratory muscle training program
Study: NCT01166503

Intervention type: PROCEDURE
Intervention: mVEP Testing
Description: Five small sensors are placed on the head which record the brain's response to moving stripes that are displayed on a computer screen. Each eye is tested while the other eye is patched. Each recording trial lasts about 10 seconds, and several trials are done for each eye.

Intervention type: PROCEDURE
Intervention: mVEP Testing
Description: Five small sensors are placed on the head which record the brain's response to moving stripes that are displayed on a computer screen. Each eye is tested while the other eye is patched. Each recording trial lasts about 10 seconds, and several trials are done for each eye.

Intervention type: PROCEDURE
Intervention: Stereoacuity Testing
Description: Subjects will have their 3D perception measured using standard clinical stereo tests (Randot, Lang, Titmus).

Intervention type: PROCEDURE
Intervention: Stereoacuity Testing
Description: Subjects will have their 3D perception measured using standard clinical stereo tests (Randot, Lang, Titmus).

Intervention type: PROCEDURE
Intervention: Optokinetic nystagmus testing
Description: Subjects will be asked to view a screen with vertical stripes moving in both leftward and rightward directions while their eye movements are recorded using a remote video-based eye tracker.

Intervention type: PROCEDURE
Intervention: Optokinetic nystagmus testing
Description: Subjects will be asked to view a screen with vertical stripes moving in both leftward and rightward directions while their eye movements are recorded using a remote video-based eye tracker.

Intervention type: PROCEDURE
Intervention: Motion detection testing
Description: Subjects will view a computer screen that has two panels of dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).

Intervention type: PROCEDURE
Intervention: Motion detection testing
Description: Subjects will view a computer screen that has two panels of dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).

Intervention type: PROCEDURE
Intervention: Motion discrimination testing
Description: Subjects will view a computer screen that has two panels of randomly moving dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).

Intervention type: PROCEDURE
Intervention: Motion discrimination testing
Description: Subjects will view a computer screen that has two panels of randomly moving dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
Study: NCT04623203

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03246139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation, imagery & execution
Description: The participants will be asked to observe movements through a video clip, practice motor imagery, and executing the movements that the participants observed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action observation
Description: The participants will be asked to observe videos and then practice what the participants observed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control treatment
Description: The participants will receive UE training without watching videos or imagining movements/tasks.
Study: NCT03721510

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PGT121 + VRC07-523LS
Description: PGT121 + VRC07-523LS, dose 30 mg/kg each, given intravenously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PGT121 + VRC07-523LS + PGDM1400
Description: PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PGT121 + VRC07-523LS + PGDM1400
Description: PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously
Study: NCT02047539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 1000 mg/day of aspirin 1000 mg/day of sugar pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04358263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring)
Description: rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring)
Description: rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
Study: NCT03404089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pharmacokinetic device
Description: MON4STRAT system: bed-side pharmacokinetic device for drug concentration measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pharmacokinetic device
Description: High performance liquid chromatography, (HPLC), the reference methods HLPC tandem mass spectrometry or Ultraviolet are using